Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients

Transplantation
D C BrennanG A Storch

Abstract

Treatment with prophylactic oral acyclovir, intravenous ganciclovir, or immunoglobulins to prevent cytomegalovirus (CMV) infection and disease in renal transplantation is associated with variable efficacy and significant expense. We studied control of CMV in renal transplant recipients using either prophylactic oral ganciclovir or deferred therapy with intensive monitoring with polymerase chain reaction (PCR) analysis. Forty-two recipients were followed for 6 months after transplantation. Ganciclovir (1000 mg p.o. t.i.d.; n=19) or acyclovir (200 mg p.o. b.i.d.; n=23) was begun at transplantation and continued for 12 weeks. PCR for CMV was performed on buffy-coat specimens every week for 15 weeks and at months 5 and 6. No patients in the ganciclovir group, compared with 14 of 23 patients (61%) in the deferred-therapy group (P<0.0001), developed CMV disease during the first 12 weeks. In the ganciclovir group, 4 of 19 patients (21%) subsequently experienced 5 episodes, whereas 14 patients in the deferred-therapy group experienced 18 episodes (P=0.013 for subjects and P=0.026 for episodes). The time to disease was also delayed in the ganciclovir group compared with the deferred-therapy group (133+/-17 days vs. 51+/-7 days; P<0.0001...Continue Reading

References

Sep 1, 1992·Mayo Clinic Proceedings·E Farrugia, T R Schwab
May 15, 1996·Transplantation·R PatelC V Paya
Feb 1, 1996·Journal of the American Society of Nephrology : JASN·J KletzmayrR Klauser
Sep 5, 1996·The New England Journal of Medicine·C S Crumpacker

❮ Previous
Next ❯

Citations

Dec 31, 1998·Springer Seminars in Immunopathology·C L Davis
Mar 15, 2005·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Christophe LegendreIsabelle Durand-Zaleski
Aug 4, 2001·Clinica Chimica Acta; International Journal of Clinical Chemistry·T C JungraithmayrT F Mueller
Sep 2, 2003·Transplantation Proceedings·O ValdezD Machado
Mar 15, 2000·Transplantation Proceedings·C Legendre, E Thervet
Dec 2, 1998·Antiviral Research·M D de JongS A Spector
Jan 31, 2002·Journal of Chromatography. B, Biomedical Sciences and Applications·A LoregianE F De Palo
Sep 26, 2001·Infectious Disease Clinics of North America·R Patel
Jun 5, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·W van der Bij, R Speich
Aug 31, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M SlifkinD R Snydman
Feb 17, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David R Snydman
Aug 31, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lorne N SmallDavid R Snydman
Mar 15, 2003·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Angelito YangoReginald Gohh
Oct 7, 2006·Current Opinion in Gastroenterology·G Meng, P D Smith
Aug 2, 2002·The Pediatric Infectious Disease Journal·Lara A Danziger-Isakov, Gregory A Storch
Aug 2, 2002·Transplantation·Carmen MuheimPascal R A Meylan
May 2, 2001·Transplantation·J Kurtz
Jul 17, 2004·Transplantation·Karen L HardingerDaniel C Brennan
Jun 18, 2010·Transplantation·Michael L SpinnerDaniel C Brennan
Nov 24, 2007·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·R Abu-Nader, R Patel
Jan 5, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Diana F FlorescuAndre C Kalil
Jun 29, 2001·Transplant Infectious Disease : an Official Journal of the Transplantation Society·J S Villacian, C V Paya
Nov 16, 2010·Journal of Transplantation·Karen L HardingerDaniel C Brennan
Aug 11, 2010·Expert Review of Anti-infective Therapy·Tomás Reischig
Apr 4, 2007·Expert Review of Anti-infective Therapy·Kabeya Mwintshi, Daniel C Brennan
Aug 19, 2007·Kidney International·S DmitrienkoUNKNOWN Genome Canada Biomarkers in Transplantation Group
Jun 21, 2011·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Kristel De KeyzerRaymond Vanholder

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.